Literature DB >> 12463079

Ovarian mass--benign or malignant?

Ann Schrecengost1.   

Abstract

Ovarian cancer strikes 23,000 American women every year, accounting for 52% of all gynecological cancer deaths. The death of comedienne Gilda Radner from ovarian cancer in 1991 brought the disease to the forefront for the American public. Unfortunately, since that time, there has been an absence of publicity about this dreadful disease. Seventy-five percent of ovarian cancers are not diagnosed until the cancer has advanced to stage III or IV for several reasons. Clinical guidelines for the diagnostic screening of ovarian cancer have not been developed, which markedly hinders the diagnosis of ovarian cancer until it is in later stages. The tumor marker CA-125 is not specific and, therefore, is an inadequate screening tool. This article discusses the epidemiology of ovarian cancer, the components of diagnostic screening, and treatment options. Nursing care of the patient undergoing surgical treatment for ovarian cancer also is discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12463079     DOI: 10.1016/s0001-2092(06)61032-6

Source DB:  PubMed          Journal:  AORN J        ISSN: 0001-2092            Impact factor:   0.676


  3 in total

1.  A giant ovarian mass in a 68-year-old female with persistent abdominal pain and elevated serum CA-125 level.

Authors:  Francesk Mulita; Panagiotis Tavlas; Ioannis Maroulis
Journal:  Prz Menopauzalny       Date:  2020-07-13

2.  Single nucleotide polymorphism of transforming growth factor-β1 and interleukin-6 as risk factors for ovarian cancer.

Authors:  Amira Ben Ahmed; Sabrina Zidi; Wassim Almawi; Ezzeddine Ghazouani; Amel Mezlini; Besma Yacoubi Loueslati; Mouna Stayoussef
Journal:  Cent Eur J Immunol       Date:  2020-11-01       Impact factor: 2.085

3.  Common variants in IL-1RN, IL-1β and TNF-α and the risk of ovarian cancer: a case control study.

Authors:  Amira Ben Ahmed; Sabrina Zidi; Ikram Sghaier; Ezzeddine Ghazouani; Amel Mezlini; Wassim Almawi; Besma Yacoubi Loueslati
Journal:  Cent Eur J Immunol       Date:  2017-08-08       Impact factor: 2.085

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.